GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has been digesting both applications for a considerable amount of time.
You may also be interested in...
Debiovision’s Sanvar Will Be Tough Sell To Advisory Panel
FDA has declared any positive results from a study of vapreotide to be statistically insignificant, immeasurably biased and possibly due to the endoscopic therapy rather than the drug.
Debiovision’s Sanvar Will Be Tough Sell To Advisory Panel
FDA has declared any positive results from a study of vapreotide to be statistically insignificant, immeasurably biased and possibly due to the endoscopic therapy rather than the drug.
GSK Files NDA For Oncology Anti-Nausea Drug
Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.